vs
Side-by-side financial comparison of FIRST COMMONWEALTH FINANCIAL CORP (FCF) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
FIRST COMMONWEALTH FINANCIAL CORP is the larger business by last-quarter revenue ($133.7M vs $103.7M, roughly 1.3× Twist Bioscience Corp). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs -29.4%, a 57.5% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 13.0%).
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
FCF vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $133.7M | $103.7M |
| Net Profit | $37.5M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | 28.1% | -29.4% |
| Revenue YoY | 13.0% | 16.9% |
| Net Profit YoY | 14.8% | 3.4% |
| EPS (diluted) | $0.37 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $133.7M | — | ||
| Q4 25 | $137.9M | $103.7M | ||
| Q3 25 | $136.0M | — | ||
| Q2 25 | $131.0M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $120.4M | — | ||
| Q3 24 | $121.2M | — | ||
| Q2 24 | $120.2M | — |
| Q1 26 | $37.5M | — | ||
| Q4 25 | $44.9M | $-30.5M | ||
| Q3 25 | $41.3M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $32.7M | — | ||
| Q4 24 | $35.8M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $37.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 40.9% | -31.7% | ||
| Q3 25 | 38.1% | — | ||
| Q2 25 | 32.1% | — | ||
| Q1 25 | 34.8% | — | ||
| Q4 24 | 37.1% | — | ||
| Q3 24 | 33.4% | — | ||
| Q2 24 | 38.7% | — |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 32.5% | -29.4% | ||
| Q3 25 | 30.4% | — | ||
| Q2 25 | 25.5% | — | ||
| Q1 25 | 27.7% | — | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 30.9% | — |
| Q1 26 | $0.37 | — | ||
| Q4 25 | $0.44 | $-0.50 | ||
| Q3 25 | $0.39 | — | ||
| Q2 25 | $0.32 | — | ||
| Q1 25 | $0.32 | — | ||
| Q4 24 | $0.35 | — | ||
| Q3 24 | $0.31 | — | ||
| Q2 24 | $0.36 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | $154.9M | — |
| Stockholders' EquityBook value | $1.6B | $456.1M |
| Total Assets | $12.3B | $638.1M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $154.9M | — | ||
| Q4 25 | $261.7M | — | ||
| Q3 25 | $262.1M | — | ||
| Q2 25 | $262.4M | — | ||
| Q1 25 | $262.7M | — | ||
| Q4 24 | $263.0M | — | ||
| Q3 24 | $136.3M | — | ||
| Q2 24 | $136.6M | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $456.1M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | $12.3B | — | ||
| Q4 25 | $12.3B | $638.1M | ||
| Q3 25 | $12.3B | — | ||
| Q2 25 | $12.2B | — | ||
| Q1 25 | $11.8B | — | ||
| Q4 24 | $11.6B | — | ||
| Q3 24 | $12.0B | — | ||
| Q2 24 | $11.6B | — |
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $187.5M | $-24.8M | ||
| Q3 25 | $49.5M | — | ||
| Q2 25 | $30.4M | — | ||
| Q1 25 | $55.9M | — | ||
| Q4 24 | $129.5M | — | ||
| Q3 24 | $53.6M | — | ||
| Q2 24 | $22.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $171.5M | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $113.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 124.3% | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 94.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 12.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.18× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 1.71× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 1.67× | — | ||
| Q2 24 | 0.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCF
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
